Information:
Error:
ID
34400
Description
Polymorphism Interaction to Predict Bevacizumab Efficacy; ODM derived from: https://clinicaltrials.gov/show/NCT01935102
Link
https://clinicaltrials.gov/show/NCT01935102
Keywords
Versions (1)
- 1/17/19 1/17/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 17, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Metastatic Breast Cancer NCT01935102
Eligibility Metastatic Breast Cancer NCT01935102
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Breast Cancer NCT01935102
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
diagnosis histologically confirmed of metastatic breast cancer
boolean
ID.2
Item
age (from 18 to 90 years)
boolean
ID.3
Item
eastern cooperative oncology group (ecog) performance status (0 or 1-2)
boolean
ID.4
Item
hormonal-receptor status (positive or negative)
boolean
ID.5
Item
previous adjuvant chemotherapy (none, anthracycline or anthracycline plus taxane)
boolean
ID.6
Item
previous hormonal therapy (adjuvant or metastatic)disease-free interval from the first diagnosis of breast cancer (≤ or >12 months)
boolean
ID.7
Item
extent of disease (≤ or >3 sites)
boolean
ID.8
Item
location of disease (viscera or bone)
boolean
ID.9
Item
disease evaluation (measurable or non-measurable)and bevacizumab maintenance (yes or no).
boolean
ID.10
Item
patients with human epidermal growth factor receptor type 2 (her2)-positive
boolean